AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology, which include Humira, Skyrizi and Rinvoq; oncology, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis and Other eye care, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. It also offers investigational asset named NX-13, oral NLRX1 agonist (a member of the NOD-like receptor family), which is in Phase II for the treatment of ulcerative colitis (UC) and Crohn's disease (CD).

• Revenue in USD (TTM)54.40bn
• Net income in USD5.95bn
• Incorporated2012
• Employees50.00k

• Location
  AbbVie Inc1 N Waukegan RdNORTH CHICAGO 60064United StatesUSA
• Phone+1 (847) 932-7900
• Fax+1 (302) 655-5049
• Websitehttps://www.abbvie.com/